<DOC>
	<DOCNO>NCT00678249</DOCNO>
	<brief_summary>This study compare FLAIR™ Endovascular Stent Graft balloon angioplasty patient stenoses venous anastomosis synthetic AV access graft .</brief_summary>
	<brief_title>Pivotal Study FLAIR Endovascular Stent Graft</brief_title>
	<detailed_description>A total 227 patient treat 16 U.S. investigational site evaluate safety effectiveness FLAIR™ Endovascular Stent Graft . This study compare FLAIR™ Endovascular Stent Graft balloon angioplasty patient stenoses venous anastomosis synthetic AV access graft .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<criteria>Male female patient 18 90 year age whose hemodialysis access synthetic AV access graft locate arm . Angiographic evidence one stenoses , 7 cm less length great equal 50 % , graftvein anastomosis synthetic AV access graft . The entire lesion must locate within 7 cm anastomosis approximately 1 cm IMPRA/Bard Device must extend nondiseased vein approximately 1 cm , 2 cm , IMPRA/Bard Device extend nondiseased AV graft . Clinical evidence hemodynamically significant stenosis . Percutaneous endovascular therapy identify lesion best treatment choice opinion investigator . Patients must able understand provide inform consent . Patients whose synthetic AV access graft implant great 30 day undergone 1 successful hemodialysis session . During primary balloon angioplasty , full expansion appropriately size angioplasty balloon , operator 's judgment , must achieve . Concomitant disease ( e.g. , terminal cancer ) medical condition likely result death patient within 6 month time implantation . Stenoses correspond thrombosis treat within 7 day . The presence second lesion access circuit less equal 3 cm edge primary lesion treat within 30 day great equal 30 % . Access circuit define area AV access graft arterial anastomosis superior vena cavaright atrial junction . The presence second lesion access circuit great 3 cm edge primary lesion great equal 30 % . Second lesion great equal 30 % must treat prior patient inclusion reduce percent stenosis le 30 % . Patients unwilling unable return followup visit patient followup visit may unreliable . Patients stent place target lesion site . Patients blood coagulative disorder sepsis . Patients IMPRA/Bard Device would require cross angle ( inflow vein synthetic AV access graft ) great 90 degree . Patients IMPRA/Bard Device would require deploy fully across elbow joint , identify radiographically combination humeroulnar joint humeroradial joint . Patients contraindication use contrast medium . Patients whose AV access graft infect . Patients currently schedule enroll investigation conflict followup test confounds data trial . Procedural use another investigational device . Patients pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Vascular Prosthesis</keyword>
	<keyword>stenosis</keyword>
	<keyword>graft</keyword>
</DOC>